Vaxcyte (PCVX) Share-based Compensation (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Share-based Compensation of $9.3 million for Q1 2026, up 75.71% year-over-year from $5.3 million in Q1 2025, and up 110.12% quarter-over-quarter from -$91.9 million in Q4 2025.
Vaxcyte (PCVX) Share-based Compensation (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Share-based Compensation for 8 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 75.71% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $15.0 million (down 79.31% YoY), while the FY2025 annual figure was $11.0 million, down 87.04% from the prior year.
- Share-based Compensation grew to $9.3 million in Q1 2026 per PCVX's latest filing, from -$91.9 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $96.8 million in Q3 2025 and bottomed at -$91.9 million in Q4 2025.
- Historically, Share-based Compensation has averaged $6.1 million across 5 years, with a median of $4.1 million in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 749.65% — and 2024, when it surged 86478.31%.
- Vaxcyte's Share-based Compensation stood at -$15.8 million in 2022, then sank by 99.85% to -$31.5 million in 2023, then jumped by 327.09% to $71.6 million in 2024, then plunged by 228.27% to -$91.9 million in 2025, then soared by 110.12% to $9.3 million in 2026.
- Business Quant data shows PCVX's Share-based Compensation at $9.3 million in Q1 2026, -$91.9 million in Q4 2025, and $96.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 41.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.24 Mn |
| Jun 30, 2026 | 41.24 Mn |
| Mar 31, 2026 | 9.30 Mn |
| Mar 31, 2026 | 9.30 Mn |
| Dec 31, 2025 | -91.86 Mn |
| Dec 31, 2025 | -91.86 Mn |
| Sep 30, 2025 | 96.84 Mn |
| Sep 30, 2025 | 96.84 Mn |
| Jun 30, 2025 | 717,000.00 |
| Jun 30, 2025 | 717,000.00 |
| Mar 31, 2025 | 5.29 Mn |
| Mar 31, 2025 | 5.29 Mn |
| Dec 31, 2024 | 71.62 Mn |
| Dec 31, 2024 | 71.62 Mn |
| Sep 30, 2024 | -25.98 Mn |
| Sep 30, 2024 | -25.98 Mn |
| Jun 30, 2024 | 21.56 Mn |
| Jun 30, 2024 | 21.56 Mn |
| Mar 31, 2024 | 17.63 Mn |
| Mar 31, 2024 | 17.63 Mn |